Roivant Sciences Ltd. (ROIV)
NASDAQ · Manufacturing · Pharmaceutical preparations
$35.80−$0.3300 (−0.91%) on the dayAs of the close; data may be delayed.
ROIV price, last 12 months
Key stats
- Previous close
- $36.13
- Open
- $36.10
- Day range
- $35.52 – $36.30
- 52-week range
- $14.59 – $42.50
- Volume
- 5.9M
- Avg volume (20 days)
- 10.8M
- Market cap
- $25.9B
Performance
1W−10.0%
1M−2.6%
3M+5.1%
6M+30.9%
YTD+65.0%
1Y+143.5%
vs S&P 500, 1Y+126.8 pts
Technicals and fundamentals
About Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $25.9B